Trial Profile

A Single Arm Phase 2 Trial of Atezolizumab With Sacituzumab Govitecan to Prevent Recurrence in Triple Negative Breast Cancer (ASPRIA)

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 30 Jan 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Atezolizumab (Primary) ; Sacituzumab govitecan (Primary)
Indications Early breast cancer; Male breast cancer; Triple negative breast cancer
Focus Therapeutic Use
Acronyms ASPRIA

Most Recent Events

22 Jan 2024 Planned End Date changed from 30 Dec 2025 to 30 Dec 2027.
22 Jan 2024 Planned primary completion date changed from 30 Dec 2023 to 30 Dec 2025.
19 Jun 2023 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com